Pellucid marginal degeneration (PMD) is an eye condition that has been around for a long time, but is still relatively unknown and poorly understood. PMD is a progressive, non-inflammatory condition that causes thinning of the cornea at the outer edge, or margin, of the eye. This can lead to decreased vision, light sensitivity, and other vision-related problems. The exact cause of PMD is unknown, but it is thought to be related to genetics, environmental factors, or a combination of both. In this article, we will explore the mysteries of PMD, discuss the symptoms, diagnosis, and treatment options, and provide an overview of the current research.
Pellucid marginal degeneration (PMD) is a progressive, non-inflammatory eye disease that affects the peripheral cornea. It is characterized by thinning of the cornea at the outer edge, or margin, of the eye. This thinning can cause decreased vision, light sensitivity, and other vision-related problems. PMD is most commonly seen in people between the ages of 20 and 40, although it can occur at any age.
The most common symptom of PMD is decreased vision in the affected eye. This can range from mild to severe, depending on the severity of the condition. Other symptoms may include light sensitivity, glare, halos around lights, double vision, and astigmatism. In some cases, the condition may also cause pain or discomfort.
PMD is typically diagnosed during a comprehensive eye exam. During the exam, the doctor will look for signs of thinning of the cornea at the outer edge of the eye. They may also use a slit lamp to examine the cornea more closely. Imaging tests, such as OCT (optical coherence tomography) or ultrasound, may also be used to confirm the diagnosis.
Treatment of PMD is aimed at relieving symptoms and preserving vision. In most cases, this can be done with glasses, contact lenses, or surgery. In severe cases, corneal transplantation may be necessary.
Currently, there is limited research on PMD, and the exact cause of the condition is unknown. However, researchers believe that genetics, environmental factors, or a combination of both may play a role. Studies have also suggested that PMD may be associated with certain autoimmune diseases, such as rheumatoid arthritis.
Pellucid marginal degeneration is a progressive, non-inflammatory eye condition that can cause decreased vision, light sensitivity, and other vision-related problems. Although the exact cause of PMD is unknown, it is thought to be related to genetics, environmental factors, or a combination of both. Treatment of PMD is aimed at relieving symptoms and preserving vision, and can include glasses, contact lenses, or surgery. Research on PMD is ongoing, and further studies are needed to better understand the condition and develop more effective treatments.
1.
Targeted radiation therapy shows near-complete response in rare sarcoma patients
2.
Dostarlimab Boosts Long-Term Survival in Endometrial Cancer
3.
Germline Profiling May Improve Risk Stratification in t-MNs
4.
Results for Prostate Cancer Are Associated With PSA Nadir 6 Months After Primary RT.
5.
Scientists call into question safety of potential new anticancer treatment
1.
Understanding Macrocytosis: Causes, Symptoms, and Treatment Options
2.
Gender-Specific Dual Antiplatelet Therapy Strategies for Women After PCI
3.
Unlocking the Mystery of Hemoglobin C Trait: A Closer Look at a Rare Blood Disorder
4.
Ferroptosis Signaling in Tumor Progression and Therapeutic Resistance
5.
Exploring New Treatment Options for Hemophilia: A Journey into the Unknown
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
2.
Navigating the Complexities of Ph Negative ALL - Part XV
3.
Clinical Insights in Hematology
4.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
5.
Updates on the First Line Management of ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation